INTRODUCTION

Platelet aggregation and the subsequent formation of blood clots are essential processes in hemostasis (Xia et al., 2012). Platelets can be activated abnormally in a pathological environment however, leading to thrombogenesis and the formation of occlusive thrombi. The circulating thrombi can occlude small blood vessels and subsequently cause various cardiovascular diseases including ischemic heart disease and stroke (Lee et al., 2014a). Therefore, the inhibition of platelet aggregation has been considered as a strategy to limit the progress of arterial thrombosis and platelet-associated cardiovascular diseases (Ruggeri, 2002).

To date, a number of anti-platelet drugs, such as clopidogrel and aspirin, have been developed and are used clinically to prevent thrombosis (Bassand, 2013). However, the use of these anti-platelet drugs is limited due to their associated side effects such as gastrointestinal bleeding and palpitation (Vaiyapuri et al., 2013). Therefore, the development of much safer and more effective anti-platelet agents is needed (Barrett et al., 2008).

Yuzu (Citrus junos sieb ex Tanaka) is a citrus fruit native to northeast Asia and can be found in Korea, China, and Japan. Citrus fruits contain dietary components such as hesperidin, naringin, luteolein, limonene, and vitamin C, which confer health benefits that include preventing cardiovascular disease and improving blood circulation. Yuzu also contains various flavonoids, such as hesperidin, naringin, rutin, rutin hydrate, narirutin, apigen-7-glucoside, quercetin, and tangeretin (Yang et al., 2013). Several studies have suggested that limonene from yuzu essential oil can be used to treat bronchial asthma due to its anti-inflammatory activities. Indeed, yuzu has been reported to inhibit the production of cytokines and reactive oxygen species, and to reduce eosinophil migration. Our previous study demonstrated that methanolic extract of yuzu has anti-platelet effects in rat blood (Yu et al., 2011). However, few studies has been reported about its underlying mechanism.

In this study, we evaluated whether the anti-platelet effect of yuzu and its components can be extended to human blood by examining whether they can inhibit aggregations induced by various agonists in human platelet rich plasma (PRP). This study also investigated the underlying mechanism of yuzu focusing on ADP granule secretion, TXB2 formations, and PLCγ/Akt signaling. The results from this study showed that ethanolic yuzu extract (YE), and its components, hesperidin and naringin, inhibited human platelet aggregation in a concentration-dependent manner. YE, hesperidin and naringin also inhibited TXB2 formation and ADP release. The phosphorylation of PLCγ and Akt was significantly inhibited by YE, hesperidin and naringin. Furthermore, we demonstrated that YE, hesperidin and naringin has anti-platelet effects in rat ex vivo studies, and lower side effects in mice tail bleeding time studies. The results from this study suggest that YE, hesperidin and naringin can inhibit human platelet aggregation, at least partly through the inhibition of PLCγ and Akt, leading to a decrease in TXB2 formation and granule secretion.

Key Words: Yuzu, Hesperidin, Naringin, Platelet, Aggregation

Inhibitory Effects of Yuzu and Its Components on Human Platelet Aggregation

Tae-Ho Kim¹, Hye-Min Kim¹, Se Won Park² and Yi-Sook Jung¹,³,*

¹College of Pharmacy, Ajou University, Suwon 443-749, ²Department of Molecular Biotechnology, College of Life and Environmental Sciences, Konkuk University, Seoul 143-701, ³College of Pharmacy, Research Institute of Pharmaceutical Sciences and Technology, Ajou University, Suwon 443-749, Republic of Korea

Abstract

Our previous study demonstrated that yuzu has an anti-platelet effect in rat blood. In the present study, we examined whether the anti-platelet effect of yuzu can be extended to human blood by investigating its ability to inhibit aggregations induced by various agonists in human platelet rich plasma (PRP). This study also investigated the underlying mechanism of yuzu focusing on ADP granule secretion, TXB2 formations, and PLCγ/Akt signaling. The results from this study showed that ethanolic yuzu extract (YE), and its components, hesperidin and naringin, inhibited human platelet aggregation in a concentration-dependent manner. YE, hesperidin and naringin also inhibited TXB2 formation and ADP release. The phosphorylation of PLCγ and Akt was significantly inhibited by YE, hesperidin and naringin. Furthermore, we demonstrated that YE, hesperidin and naringin has anti-platelet effects in rat ex vivo studies, and lower side effects in mice tail bleeding time studies. The results from this study suggest that YE, hesperidin and naringin can inhibit human platelet aggregation, at least partly through the inhibition of PLCγ and Akt, leading to a decrease in TXB2 formation and granule secretion.

Key Words: Yuzu, Hesperidin, Naringin, Platelet, Aggregation
by various agonists in human platelet rich plasma (PRP). We further investigated possible signaling mechanisms for their anti-platelet effects in human blood.

**MATERIALS AND METHODS**

**Reagents**

Ethanol extract of yuzu fruit (YE) was obtained from Konkuk University (Seoul, Republic of Korea). Briefly, yuzu were harvested in the southern region of Korea, Goheung (Republic of Korea). Whole fruits, including seeds, pulp and skin, were extracted with 70% ethanol and dried to remove the solvent, then dissolved in saline for the experiments. Hesperidin, naringin, apyrase, acetyl-salicylic acid (ASA), bovine serum albumin (BSA), fura 2-AM, β-nicotinamide adenine dinucleotide (reduced form, β-NADH) and pyruvic acid were obtained from Sigma Chemical Co. (St. Louis, MO, USA). Collagen, thrombin, adenosine diphosphate (ADP), arachidonic acid (AA), and luciferin-luciferase reagent were purchased from Chrono-Log Co. (Harverstown, PA, USA). Antibodies against phospholipase Cγ (PLCγ), phosphor-PLCγ, PI3K/protein kinase B (Akt), and phospho-Akt were purchased from Cell Signaling (Danvers, MA, USA).

**Animals**

Animals were purchased from Samtako Laboratory Animal Center (Suwon, Korea). Sprague-Dawley (SD) rats (8 weeks, 220-240 g) and ICR mice (8 weeks, 34-40 g) were used for experiments. They were housed in a conventional animal facility with free access to food and water in a temperature- and relative-humidity-controlled environment under a 12-h light/12-h dark schedule. The animals were acclimatized for a minimum of 7 days before experiments were performed. Animal study protocols conformed to guidelines in the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and were approved by the Committee on Animal Research at Ajou University (Seoul, Republic of Korea). Briefly, SD rats weighing 200-240 g were lightly anesthetized with diethyl ether. A volume of 8-10 mL of blood was collected from the abdominal aorta of each rat into a syringe containing 3.8% sodium citrate. The ratio of blood to 3.8% sodium citrate was adjusted to 1:9 v/v. After centrifugation at 150 g for 10 min at room temperature, the supernatant (PRP) was used for the aggregation study.

**Preparation of platelet rich plasma (PRP) from human blood**

Human platelet suspensions were supplied by the Red Cross (Suwon, Korea). Human blood was collected from healthy human volunteers free of medications as indicated by the Red Cross guide. Human PRP were diluted with Tyrode’s solution (11.9 mM NaCl, 2.7 mM KCl, 2.1 mM MgCl₂, 0.4 mM NaH₂PO₄, 11.9 mM NaHCO₃, 11.1 mM glucose, and 3.5 mg/mL bovine serum albumin, pH 7.2).

**Preparation of PRP from Rat**

PRP from rat blood was prepared as described previously (Jung et al., 2002; Eskandariany et al., 2014). Briefly, SD rats weighing 200-240 g were lightly anesthetized with diethyl ether. A volume of 8-10 mL of blood was collected from the abdominal aorta of each rat into a syringe containing 3.8% sodium citrate. The ratio of blood to 3.8% sodium citrate was adjusted to 1:9 v/v. After centrifugation at 150 g for 10 min at room temperature, the supernatant (PRP) was used for the aggregation study.

**Platelet aggregation study**

Platelet aggregation was performed by the previously described turbidimetric method using an aggregometer (Chrono-log, Havertown, USA) (Pyo et al., 2002; Kim et al., 2011). Briefly, PRP was incubated at 37°C for 5 min with different concentrations of samples (YE, hesperidin, and naringin) in the aggregometer while stirring at 1000 rpm. PRP was then stimulated with different aggregating agents at the following final concentrations: collagen, 2 μg/mL; thrombin, 0.4 U/mL; ADP, 10 μM; AA, 100 μM (Chrono-Log, USA). The extent of platelet aggregation was estimated by measuring the maximum height above the baseline reached by the aggregation curve within 5 min following stimulation.

**ATP release assay**

Detection of ATP release was performed as previously described (Flevaris et al., 2009). Washed platelets (WPs) were preincubated for 3 min at 37°C with various concentrations of samples and then stimulated with collagen. After the reaction was terminated, samples were centrifuged and supernatants were collected for the assay. ATP release was measured in a luminometer (GloMax 20/20, Promega, Madison, WI, USA) using an ATP assay kit (Biomedical Research Service Center, Buffalo, NY, USA).

**Measurement of Thromboxane B₂ (TXB₂) Production**

Measurement of TXB₂ production was conducted using a TXB₂ EIA kit (Cayman Chemical Co, Ann Arbor, MI, USA) as previously described (Cho et al., 2011; Seo et al., 2011). PRP (2×10¹⁰ platelets/mL) was incubated for 3 min in the presence or absence of samples. Collagen (2 μg/mL) was added and the mixture was incubated at 37°C for 5 min with stirring. EDTA (10 mM) was added to stop TXB₂ production. After centrifugation at 12,000 g for 3 min, the amount of TXB₂ was measured according to the manufacturer’s instructions.

**Western blot analysis**

The immunoassay was performed as previously described (Endale et al., 2012). The WPs (2×10¹⁰ platelets/mL) were stimulated with collagen (2 μg/mL) in the presence or absence of samples. Reactions were terminated by adding 10 mM EDTA and the platelets were centrifuged at 12,000 g for 3 min. After adding ice-cold platelet lysis buffer (1% NP40, 15 mM HEPES, 75 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM sodium fluoride (NAF), 1 mM NaVO₄, 1 μg/ml leupeptin, and 1 μg/ml aprotinin; pH 7.4), lysates were centrifuged at 13,000 g for 10 min at 4°C. The supernatants were collected and protein concentration was determined using a BCA protein assay (Thermo Scientific, IL, USA). Equal volumes of protein were resolved using SDS-PAGE (10%) and transferred to Polyvinydene Difluoride (PVDF) membranes. The PVDF membranes were blocked with 5% nonfat dry milk in TBS and incubated with the primary antibody diluted in TBS buffer (1:1000 ratio, 4°C overnight). Immunoblots were incubated with a horse radish peroxidase (HRP)-conjugated secondary antibody and the immune-reactive bands were visualized with a LAS 4000 (Fuji, Honshu, Japan) using a western blot detection system (WestZol, Intron, Seoul, Republic of Korea).

**Ex vivo collagen-induced platelet aggregation study**

SD rats were orally administered saline and samples, or ASA (50 mg/kg). Two hours later, rat blood samples were collected and the platelet aggregation study was performed as described above (Kim et al., 2011).
In vivo tail bleeding time study

Bleeding times were determined as previously described (Cho et al., 2008; Lee et al., 2014b). Male ICR mice, weighing 35-40 g, were used in this experiment. Mice were fasted for 24 h before experiments. For in vivo studies, the YE was suspended in saline and aspirin was suspended in 10% Tween 80-saline. ICR mouse were orally administered saline and YE (100 mg/kg), hesperidin (10 mg/kg), naringin (10 mg/kg), or ASA (50 mg/kg) once a day for 1 day, or for 7 days. Two hours after the last administration, mice were anesthetized with sodium pentobarbital (75 mg/kg, IP), and individually placed on a hotplate to maintain body temperature at 37°C. In each case, the tail was transected 3 mm from its tip with a razor blade, and then immersed in a 15-ml clear conical tube containing normal saline prewarmed to 37°C. Times to blood flow cessation (defined as no bleeding for 15 s) were measured. Data are expressed as means ± SEM.

Statistical analysis

All data are expressed as means ± SEMs of at least four different experiments. Statistical analysis was performed using one way ANOVA followed by Dunnett’s test or the paired t-test using Sigma Stat statistical software (San Rafael). Significance was accepted for p-values of <0.05.
**Fig. 3.** Inhibitory effects of hesperidin on human platelet aggregation. PRP was preincubated for 5 min with various concentrations of hesperidin at 37°C before being aggregated with collagen 2 μg/ml (A), ADP 10 μM (B), AA 100 μM (C), and thrombin 0.4 U/ml (D). Data are expressed as means ± SEM (n=5). *p<0.05 vs. vehicle.

**Fig. 4.** Inhibitory effects of naringin on human platelet aggregation. PRP was preincubated for 5 min with various concentrations of naringin at 37°C before being aggregated with collagen 2 μg/ml (A), ADP 10 μM (B), AA 100 μM (C), and thrombin 0.4 U/ml (D). Data are expressed as means ± SEM (n=5). *p<0.05 vs. vehicle.
RESULTS

Effect of YE on human platelet aggregation

We evaluated the effect of YE on platelet aggregation induced by collagen, ADP, AA, and thrombin in human PRP. As shown in Fig. 1, YE (3, 10 mg/ml) significantly inhibited collagen-induced platelet aggregations (59.3 ± 2.0, 99.0 ± 0.5%, respectively), ADP-induced platelet aggregations (38.1 ± 3.0, 96.2 ± 1.2%, respectively), and AA-induced platelet aggregations (61.7 ± 0.7, 99.5 ± 0.5%, respectively) (Fig. 2A-C). YE at concentrations of 1, 3, and 10 mg/ml also significantly inhibited thrombin-induced platelet aggregations (16.8 ± 2.8, 36.1 ± 1.5, 97.4 ± 1.9% respectively) (Fig. 2D).

Effect of hesperidin on human platelet aggregation

We evaluated the effect of hesperidin on platelet aggregation induced by collagen, ADP, AA, and thrombin in human PRP. Hesperidin at concentrations of 0.1, 0.3, and 1 mg/ml significantly inhibited collagen-induced platelet aggregations (30.4 ± 4.9, 50.4 ± 2.6, 90.6 ± 5.5%, respectively), and thrombin-induced platelet aggregations (13.2 ± 1.5, 33.0 ± 0.9, 46.1 ± 2.5%, respectively) (Fig. 3A, D). Hesperidin at concentrations of 0.3 and 1 mg/ml also significantly inhibited ADP-induced platelet aggregations (12.4 ± 1.4, 72.1 ± 2.2%, respectively), and AA-induced platelet aggregations (57.9 ± 1.6, 95.3 ± 2.4%, respectively) (Fig. 3B, C).

Effect of naringin on human platelet aggregation

We evaluated the effect of naringin on human platelet aggregation induced by collagen, ADP, AA, and thrombin in human PRP. Naringin at concentrations of 0.1, 0.3, and 1 mg/ml significantly inhibited collagen-induced platelet aggregations (61.7 ± 0.7, 99.5 ± 0.5%, respectively), and thrombin-induced platelet aggregations (19.3 ± 1.5, 33.0 ± 0.9, 46.1 ± 2.5%, respectively) (Fig. 4A, C, D). Naringin at concentrations of 10 mg/ml also significantly inhibited ADP-induced platelet aggregations (20.0 ± 1.0, 46.8 ± 2.0, 83.7 ± 0.9%, respectively), and AA-induced platelet aggregations (57.9 ± 1.6, 95.3 ± 2.4%, respectively) (Fig. 4B).

Effect of YE, hesperidin, and naringin on dense granule secretion in human platelets

To investigate the mechanism underlying the anti-platelet effects of YE, hesperidin, and naringin, we evaluated their effects on ATP release, which is a well-known biomarker of granule secretion from activated platelets. Collagen-induced ATP release was significantly inhibited by 10 mg/ml of YE (85%), 1 mg/ml of hesperidin (77%) and 1 mg/ml of naringin (85%) (Fig. 5A).

Effect of YE, hesperidin, and naringin on TXB<sub>2</sub> formation in human platelets

To investigate another potential mechanism underlying the anti-platelet effects of YE, hesperidin, and naringin, we evaluated their effects on TXB<sub>2</sub> formation. Collagen-induced TXB<sub>2</sub> formation (3,034.2 ± 27.2 μM) was significantly inhibited by 10 mg/ml of YE (1,930.7 ± 23.5 μM), 1 mg/ml of hesperidin (2,378.4 ± 57.5 μM), and 1 mg/ml of naringin (2,014.0 ± 58.3 μM) (Fig. 5B).

Effect of YE, hesperidin, and naringin on phosphorylation of PLCγ and Akt in human platelet

As a candidate for the signaling pathways, we evaluated the phosphorylation of proteins in the collagen-induced pathway. YE (3, 10 mg/ml), hesperidin (0.1, 0.3, 1 mg/ml), and naringin (0.1, 0.3, 1 mg/ml) significantly inhibited the phosphorylation of Akt and PLCγ (Fig. 6).

Effect of YE on platelet aggregation ex vivo

We also evaluated the effect of YE on collagen-induced platelet aggregation. Oral administration of 100 mg/kg YE, as well as 10 mg/kg hesperidin and naringin significantly inhibited collagen-induced platelet aggregation (29.8 ± 1.8, 24.3 ± 1.9, 23.4 ± 0.7% respectively). However, the effects were less than that of ASA (40.4 ± 2.1%) (Fig. 7).

Effect of YE on bleeding time

We also determined bleeding times in ICR mice to evaluate the side effects of YE. Bleeding time (66.2 ± 4.7 s) in mice was prolonged by oral administration of 100 mg/kg YE (127.4 ± 5.1 s), and 10 mg/kg hesperidin (120.0 ± 2.3 s) and naringin (121.2 ± 2.5 s). However, the extent of prolongation was significantly less than that of ASA (197.0 ± 10.1 s) (Fig. 8).
DISCUSSION

The present study demonstrates for the first time that YE can attenuate aggregation of human platelets and that it also inhibits TXA2 production, granule secretion and phosphorylation of the platelet aggregation related proteins, Akt and PLCγ2. Platelets have the functions of activation, aggregation, adhesion and secretion (Xia et al., 2012). Under pathologic conditions, platelets bind with extracellular matrix, such as collagen or thrombin generated at the site of injury, leading to platelet activation and thrombus formation (Yu et al., 2011). While our previous study indicated that the methanolic extract of yuzu induces inhibitory effects on rat platelets (Yu et al., 2011), the results from the present study confirmed that the anti-platelet potential of YE and its components can be extended to the human blood by showing that the aggregation of human PRP was significantly inhibited by YE, hesperidin and naringin in a concentration-dependent manner.

The mechanisms responsible for platelet activation and increased platelet aggregation have been reported to involve various signaling pathways that depend on agonists. Indeed, the responses of platelets to collagen stimulation are known to be mediated via glycoprotein VI (GPVI) and integrin a2b1, while the responses to thrombin are largely mediated through G-protein coupled protease-activated receptors (PARs). Collagen induces platelet activation through Src family kinase mediated Fc receptor g-chain tyrosine phosphorylation followed by Syk and linker for activation of T cells (LAT) tyrosine phosphorylation. Activated LAT and PI3K lead to 1,2-diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3) release, PKC activation, and Ca2+ mobilization through tyrosine phosphorylation of PLCγ2 (Endale et al., 2012). The PLCγ/PKCδ/extracellular signal-regulated kinases (ERK) and/or the p38 mitogen-activated protein kinases (p38) signaling pathway are activated in addition to PI3K/protein kinase B (Akt) signaling. Akt, PKCδ, ERK and p38 are common molecules in platelet activation signaling pathways, whereas PLCγ2 is a molecule that plays a specific role in the collagen-induced platelet acti-
viation pathway (Liou et al., 2012). Upon exposure to activating agonists, such as collagen and thrombin, platelets liberate AA and the liberated AA is converted by cyclooxygenase and TXA2 synthase into TXA2. ADP is known to be secreted from dense granules in activated platelets. The α-granules contain many proteins such as fibrinogen, von Willebrand factor, and P-selectin. Dense granules contain molecules such as ADP, ATP, and calcium (Vaiyapuri et al., 2013). When ADP is re-leased, it binds to ADP receptors, such as P2Y1 and P2Y12, in an autocrine and paracrine manner, leading to platelet activation and aggregation. P2Y1 receptor activation regulates Ca2+-dependent signaling, whereas P2Y12 receptor activation regulates integrin αIIb3. The results from our study showed that YE has a greater effect on granule secretion and TXB2 formation, while hesperidin and naringin have stronger effects on the phosphorylation of PLCγ and Akt. To determine whether the anti-platelet effects of YE and its components are maintained in vivo, we evaluated the effects of YE, hesperidin, and naringin on rat platelet aggregation ex vivo after oral administration. YE and its components had anti-platelet effects ex vivo. We then evaluated the side effects of YE and its components by performing a bleeding time assay. YE and its components prolonged bleeding time, but the extent of prolongation was less than that of ASA. These results suggest that YE intake can prevent uncontrolled platelet activation with fewer side effects than ASA.

In conclusion, our findings from this study suggest that YE and its components induce a significant anti-platelet activity in human blood and therefore, may have therapeutic potential for the prevention of platelet-associated cardiovascular diseases.

ACKNOWLEDGMENT

This work was supported by a grant from the Next-Generation BioGreen 21 Program (No.PJ009074), Rural Development Administration, Republic of Korea.

REFERENCE


